Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.

Overview of attention for article published in Journal of Managed Care & Specialty Pharmacy, May 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

news: 2 news outlets
blogs: 1 blog

twitter: 2 X users

Readers on

mendeley: 23 Mendeley

Summary News Blogs X

So far, Altmetric has seen 3 news stories from 2 outlets.

Side Effects are Limiting GLP-1 Drug Efficacy: How Can Personalization Offer a Solution?

Health Reporter, 23 Aug 2024

An Efficient Approach to Expand Equitable Access to Antiobesity Medications: Deprescribing After Weight Loss Plateau

AJMC, 29 Jul 2024

Am J Manag Care. 2024;30(8):In Press _____ Obesity is a significant population health crisis impacting more than 120 million…

Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree

Health Reporter, 13 Jul 2024

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.